Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles J Ferro

Showing results (11-20 of 176) with videos related to

Pageof 18
Sort By:
Arthritis and Rheumatism|January 30, 2010
An increased risk of ischemic heart disease in Wegener's granulomatosis: comment on the article by Faurschou et alMatthew D Morgan, Charles J Ferro, Lorraine Harper
European Heart Journal. Quality of Care & Clinical Outcomes|February 24, 2018
SPRINTing towards trials of blood pressure reduction to reduce CKD progression?William E Moody, Charles J Ferro, Jonathan N Townend
American Heart Journal|July 29, 2014
The EARNEST study: interarm blood pressure differences should also be recordedWilliam E Moody, Charles J Ferro, Jonathan N Townend, et al.
Circulation|October 21, 2015
Letter by Edwards et al Regarding Article, "Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction"Nicola C Edwards, Manvir K Hayer, Charles J Ferro
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 7, 2023
Heart disease and stroke statistics 2023 update from the American Heart Association-implications for nephrologyNicola C Edwards, Charles J Ferro, Jonathan N Townend
Clinical Kidney Journal|May 2, 2022
Blood pressure targets in CKD 2021: the never-ending guidelines debacleSol Carriazo, Pantelis Sarafidis, Charles J Ferro, et al.
Journal of Human Hypertension|March 3, 2021
Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunctionCharalampos Loutradis, Anna Price, Charles J Ferro, et al.
The New England Journal of Medicine|March 17, 2021
Finerenone and Chronic Kidney Disease Outcomes in Type 2 DiabetesNicola C Edwards, Charles J Ferro, Jonathan N Townend
American Journal of Nephrology|July 10, 2020
SGLT-2 Inhibitors to Treat Hyponatremia Associated with SIADH: A Novel Indication?Pantelis Sarafidis, Charalampos Loutradis, Charles J Ferro, et al.
Pharmacology Research & Perspectives|September 29, 2021
Polypharmacology of clinical sodium glucose co-transport protein 2 inhibitors and relationship to suspected adverse drug reactionsKaran Matharu, Kiran Chana, Charles J Ferro, et al.
Pageof 18

Showing results (11-20 of 176) with videos related to

Sort By:
Pageof 18
Arthritis and Rheumatism|January 30, 2010
An increased risk of ischemic heart disease in Wegener's granulomatosis: comment on the article by Faurschou et alMatthew D Morgan, Charles J Ferro, Lorraine Harper
European Heart Journal. Quality of Care & Clinical Outcomes|February 24, 2018
SPRINTing towards trials of blood pressure reduction to reduce CKD progression?William E Moody, Charles J Ferro, Jonathan N Townend
American Heart Journal|July 29, 2014
The EARNEST study: interarm blood pressure differences should also be recordedWilliam E Moody, Charles J Ferro, Jonathan N Townend, et al.
Circulation|October 21, 2015
Letter by Edwards et al Regarding Article, "Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction"Nicola C Edwards, Manvir K Hayer, Charles J Ferro
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 7, 2023
Heart disease and stroke statistics 2023 update from the American Heart Association-implications for nephrologyNicola C Edwards, Charles J Ferro, Jonathan N Townend
Clinical Kidney Journal|May 2, 2022
Blood pressure targets in CKD 2021: the never-ending guidelines debacleSol Carriazo, Pantelis Sarafidis, Charles J Ferro, et al.
Journal of Human Hypertension|March 3, 2021
Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunctionCharalampos Loutradis, Anna Price, Charles J Ferro, et al.
The New England Journal of Medicine|March 17, 2021
Finerenone and Chronic Kidney Disease Outcomes in Type 2 DiabetesNicola C Edwards, Charles J Ferro, Jonathan N Townend
American Journal of Nephrology|July 10, 2020
SGLT-2 Inhibitors to Treat Hyponatremia Associated with SIADH: A Novel Indication?Pantelis Sarafidis, Charalampos Loutradis, Charles J Ferro, et al.
Pharmacology Research & Perspectives|September 29, 2021
Polypharmacology of clinical sodium glucose co-transport protein 2 inhibitors and relationship to suspected adverse drug reactionsKaran Matharu, Kiran Chana, Charles J Ferro, et al.
Pageof 18